Deprioritization of Ongoing Clinical Trials.

Area of Science:

• Clinical research ethics
• Evidence-based medicine
• Health policy

Background:

• Ethical clinical trials require a favorable risk-benefit balance at initiation.
• Study value can decrease mid-trial due to external evidence shifts.
• The COVID-19 pandemic revealed critical gaps in monitoring trial relevance.

Purpose of the Study:

• To identify and describe the challenges of maintaining clinical trial relevance and value post-initiation.
• To explore the ethical dynamics surrounding studies that lose expected value.
• To propose a provisional framework for addressing these issues.

Main Methods:

• Literature review on clinical trial ethics and value.
• Analysis of the ethical considerations in ongoing studies.
• Case study examination, referencing the COVID-19 pandemic context.
• Development of a provisional framework for ongoing trial assessment.

Main Results:

• Situations where trial value diminishes mid-study are under-addressed.
• Significant material and human capital costs are associated with uninformative studies.
• Ethical dilemmas arise when trials persist despite declining relevance.
• A framework is proposed to guide the assessment of continued trial value.

Conclusions:

• Ensuring ongoing scientific relevance and value in clinical trials is an ethical imperative.
• The COVID-19 pandemic underscored the need for adaptive trial monitoring.
• Further empirical research is needed to validate proposed solutions.
• A structured approach is necessary to navigate ethical challenges of declining trial value.